Core Viewpoint - The development of biomanufacturing is crucial for enhancing new productive forces in China, with the potential to account for one-third of global manufacturing output by the end of the century, creating a market worth $30 trillion [4]. Group 1: Biomanufacturing Industry Insights - Biomanufacturing is becoming a focal point in national strategic competition, with the U.S. aiming to replace 90% of traditional plastics with bio-based products within 20 years, and the EU implementing a carbon border adjustment mechanism by 2027 [4]. - The technology demonstrates significant potential in addressing resource and environmental challenges, such as using a 50 cubic meter bioreactor to produce artemisinin, which saves 30,000 acres of arable land [4]. - Each ton of bio-based plastic can reduce carbon dioxide emissions by 0.6 tons compared to traditional plastics, contributing to carbon neutrality goals [4]. Group 2: Applications and Innovations - Revolutionary breakthroughs in biomanufacturing are emerging, including the development of biological pheromones for precise pest control, which can replace high-residue pesticides [5]. - The cost of products like hyaluronic acid has significantly decreased due to biomanufacturing, and carbon dioxide is being explored as a third-generation raw material [5]. - The integration of artificial intelligence accelerates innovation, enabling the industrial production of scarce components like catechin from green tea [5]. Group 3: Challenges and Recommendations - Despite holding 70% of global fermentation capacity, the biomanufacturing industry in China faces challenges such as a lack of proprietary strains and limitations in core software tools [5]. - There is a call for enhanced top-level design to focus on cutting-edge areas like carbon dioxide bioconversion and future food manufacturing, aiming to address both green chemical alternatives and protein supply security [5].

Group 1 - Nanyang City has launched an action plan to develop a biomanufacturing pilot zone, focusing on project traction, platform construction, and element guarantee to accelerate the transformation and industrial application of scientific research achievements [1] - The Henan Qianmu Biopharmaceutical Project, jointly invested by Qianhong Pharmaceutical and Muyuan Group, has been put into production, filling the gap in high-end heparin raw materials in Henan Province and integrating Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang has 46 biopharmaceutical enterprises above designated size, with an estimated total industry chain output value of approximately 40 billion yuan in 2024, and 25 provincial-level innovation platforms, supporting a full chain from R&D to pilot testing to industrialization [1] Group 2 - Nanyang is actively developing synthetic biology, leveraging the talent and technological advantages of the Nanyang Synthetic Biology Research Institute to create a new generation of efficient, low-consumption, and green bioprocessing platforms [1] - The city is focusing on the industrialization of high-efficiency biosynthesis projects for essential amino acids and microbial synthesis of oils, as well as the development of high-end bio-based materials and new food products like "artificial protein" [1] - The construction of strategic leading laboratories is being strengthened, with the first technology transfer project from the Nanyang pilot base entering mass production, expected to generate an annual output value of about 240 million yuan [2] Group 3 - Nanyang has established a technology innovation system that integrates production, education, research, and application, relying on key research platforms like Muyuan Laboratory and local universities [2] - The city has formed a favorable development pattern characterized by leading enterprises, chain-driven growth, strong product R&D capabilities, and wide market coverage in the biomanufacturing industry [2]